Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Medivolve Inc MEDVF

Medivolve, Inc. is a Canada-based healthcare technology company. The Company has two business units: Medivolve Pharmacy Division (MPD) and Collection Sites Diagnostics (CSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine, and psychiatry to patients in Southern California. CSD’s software platform, Electronic Health Records app (EHR), is focused on supporting clinical staff, is a series of assets and functionalities that enhance the customer experience and provide an end-to-end lab solution. The Company, through its subsidiaries, Medivolve Pharmacy Inc., and Kedy Ying Jao D.O., a medical corporation, operate a distributed network of two retail patient-care locations in California, United States. The Company has served hundreds of thousands of patients across the United States and facilitated more than 1,533,000 clinical tests.


OTCPK:MEDVF - Post by User

Post by Hiddensecretson Mar 23, 2021 3:05pm
233 Views
Post# 32859622

Following honest webinar: MEDV - upgraded to a BUY

Following honest webinar: MEDV - upgraded to a BUYI spoke to my banker and i was informed that the selloff is over.

They attended the webinar and it was a toned down version of reality with expectations of cubes being drastically cut down and kept at 48 for the remainder of the year, down from the hyped level of 2,000 cubes.

The company has also showed a willingness to pivot away from poor cubes sales.

Reasonable expectation of revenue put at $ 35 million per year USD.


CATALYSTs      Nutrcell orders pending with several institutions

                         Awaiting confirmation of govnt contracts on vaccination in California - $ 40 per shot.

                         Blowfish technology 2 month testing completed in May 2021 - then to FDA for approval

I hope my banker is right.

MPO


<< Previous
Bullboard Posts
Next >>